Results 51 to 60 of about 60,346 (233)

Long‐Term Control of Human Papillomavirus‐Related Focal Epithelial Hyperplasia in an Human Immunodeficiency Virus‐Positive Patient Using Methylene Blue‐Mediated Photodynamic Therapy. A Case Report

Lasers in Surgery and Medicine, EarlyView.
ABSTRACT Background Human papillomavirus (HPV) infections are a major cause of oral lesions, and in individuals living with HIV, lesions such as focal epithelial hyperplasia (FEH) may persist or exhibit atypical features, potentially progressing to more severe conditions if untreated.
Juliana Cristina Oliverio de Araújo, Hermano Camelo Paiva, Paula Margarida Meyer Faara, Og Fray Junior, Martha Simões Ribeiro   +4 more
wiley   +1 more source

Unusual case of lamivudine-associated skin rashes in an HIV/AIDS patient: a case presentation

Archives of Pharmacy Practice, 2017
In patients with human immunodeficiency virus (HIV) infection, lamivudine is used as a first-line drug for antiretroviral therapy. Lamivudine is relatively nontoxic in nature, and it can also be used during pregnancy.
Kashif U Khan, Amer H Khan, Syed A Sulaiman, Chow T Soo, Syed I Ahmad   +4 more
doaj   +1 more source

Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now [PDF]

, 2015
Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver
Cuestas, María Luján, Eguibar, Nair, Gonzalez, Rodrigo Horacio, Nusblat, Alejandro David, Perazzo, Priscila   +4 more
core   +1 more source

Emerging Therapeutic Strategies in Anti‐Aging Medicine: A Comprehensive Review

Medicine Bulletin, EarlyView.
ABSTRACT Aging is orchestrated by interconnected hallmarks such as genomic instability, mitochondrial dysfunction, cellular senescence, and disrupted intercellular communication, which collectively drive chronic disease progression. Recent advances have expanded therapeutic opportunities to include pharmacological agents, gene and epigenome editing ...
Yundong Peng, Rui Li, Huan Li, Jun Zhou, Xuanshi Liu, Guilherme Valente, Tatiana de Campos Melo, Sifan Chen, Lei Gu   +8 more
wiley   +1 more source

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization [PDF]

, 2015
Current guidelines recommend treatment optimization in virologically suppressed patients through switching/ simplification strategies to minimize long-term toxicities and improve adherence. The assessment of inflammation/ coagulation profiles may support
FALASCA, FRANCESCA, FANTAUZZI, Alessandra, Floridia, Marco, MEZZAROMA, Ivano, SPANEDDA, Pierpaolo, TURRIZIANI, Ombretta, VULLO, Vincenzo   +6 more
core  

IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pathogenic variants in IKZF1 (IKAROS) are linked to immunodeficiency, malignancy, and immune dysregulation. We describe a family with a rare IKZF1 variant presenting with humoral immunodeficiency and thrombotic thrombocytopenic purpura (TTP). A non‐consanguineous family was clinically monitored; clinical, immunological, and genetic data (exome
Ilia Spivak, Daniella Magen, Karin Weiss, Tamar Paperna, Suhair Hanna, Amos Etzioni, Adi Miller‐Barmak, Yonatan Butbul Aviel   +7 more
wiley   +1 more source

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

BMC Infectious Diseases, 2011
Background Interferon alpha (IFNα) therapy has been widely used in the treatment of chronic hepatitis B (CHB) for decades. Nucleos(t)ide analogues are also increasingly used to treat CHB recently.
Zhang Yu-guo, Ren Wei-guang, Kong Ling-bo, Wang Mao-rong, Li Wen-cong, Nan Yue-min   +5 more
doaj   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy, Boyd, Braitstein, Calmy, Calmy, Chaiwarith, Colebunders, Daniel O'Brien, Ferradini, Gallant, Galárraga, Ivers, Laurent, Ledergerber, Mar Pujades-Rodríguez, Mocroft, Nicastri, Orrell, Pierre Humblet, Renaud-Théry, Srasuebkul, Sungkanuparph, Vasan, Vekemans, Walmsley   +24 more
core   +2 more sources

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, EarlyView.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source